Protective effects of Salvianic acid A against multiple-organ ischemia-reperfusion injury: a review

Shiyu Yang; Heming Chen; Wei Su; Yunchun Luo; Jun Liao; Yun Wang; Liyan Xiong; Chuan Zhang; Fei Li; Zhe-Sheng Chen; Tingfang Wang

doi:10.3389/fphar.2023.1297124

Protective effects of Salvianic acid A against multiple-organ ischemia-reperfusion injury: a review

Front Pharmacol. 2023 Nov 27:14:1297124. doi: 10.3389/fphar.2023.1297124. eCollection 2023.

Authors

Shiyu Yang^#¹, Heming Chen^#¹, Wei Su^#¹, Yunchun Luo¹, Jun Liao¹, Yun Wang¹, Liyan Xiong¹, Chuan Zhang¹, Fei Li², Zhe-Sheng Chen³, Tingfang Wang¹

Affiliations

¹ School of Medicine, Shanghai University, Shanghai, China.
² Shanghai Eighth People's Hospital, Shanghai, China.
³ Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, New York, NY, United States.

^# Contributed equally.

Abstract

Ischemia-reperfusion (I/R) injury refers to a new injury caused by reperfusion after the restoration of ischemic tissue or organ blood supply. Salvianic acid A (danshensu) is a primary active ingredient extracted from Salvia miltiorrhiza. It has a protective function against I/R injury in the cardiovascular system, brain, liver, kidney, gastrointestinal tract, and other organs. This article reviews evidence of the protective effects of Salvianic acid A and its potential mechanisms of action in organ I/R injury protection. The aim of this review is to investigate the role of Salvianic acid A in the treatment of I/R injury, providing a reference resource that could facilitate subsequent studies.

Keywords: Salvianic acid A; ischemia-reperfusion injury; mechanism of action; multiple organs; protective effects.

Publication types

Review

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported in part by the Natural Science Foundation of Shanghai (Grant No. 20ZR1420000), the Science and Technology Support Project in the Biomedical Field of Science, and the Technology Innovation Action Plan of Shanghai Science and Technology Commission (Grant No. 21S21902100).